Frontera Therapeutics is at the forefront of gene therapy development, leveraging its APEX Technology & Manufacturing Platform to create innovative adeno-associated virus (AAV) gene therapies. This platform integrates advanced vector design, efficient manufacturing processes, and early clinical data access, enabling the rapid development of gene therapy products. Frontera's approach includes the optimization of AAV vectors tailored for specific indications, employing techniques such as gene replacement, silencing, and editing. The company emphasizes the importance of capsid selection, engineering, and discovery to enhance the delivery and efficacy of gene therapies, ensuring that the AAV capsids effectively target the desired cell types while minimizing potential adverse effects.

Frontera's commitment to quality is evident in its state-of-the-art Good Manufacturing Practice (GMP) facilities, which adhere to global regulatory standards. These facilities allow for comprehensive control over product supply and quality throughout the development process. The company employs cutting-edge technologies for assay and disease modeling, utilizing in vitro and in vivo systems to evaluate the safety and efficacy of its gene therapies. With a focus on addressing a wide range of diseases, including ophthalmic and cardiovascular conditions, Frontera is positioned to make significant advancements in the field of gene therapy, aiming to meet the urgent medical needs of patients worldwide.

China

Frontera is a leading clinical-stage biotechnology company that seeks to develop the best gene therapy medicines to improve the lives of patients across multiple disease areas.

Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.

Frontera Therapeutics

Company Details